BMS Opdivo fails in small cell lung cancerBristol-Myers Squibb has said its Opdivo immunotherapy has failed to improve on standard of care in patients with Share XBMS Opdivo fails in small cell lung cancerhttps://pharmaphorum.com/news/bms-opdivo-fails-in-small-cell-lung-cancer/
BMS invests $12m in cancer immunotherapy tie-up with CompugenBristol-Myers Squibb has invested $12 million in Compugen, a biotech that is investigating a new approach that could Share XBMS invests $12m in cancer immunotherapy tie-up with Compugenhttps://pharmaphorum.com/news/bms-invests-12m-in-cancer-immunotherapy-tie-up-with-compugen/
Allogene astounds Wall Street with $324m IPO to fund cell therapy R&DGreat things were expected of Allogene Therapeutics’ IPO this week – the company is led by Arie Belldegrun Share XAllogene astounds Wall Street with $324m IPO to fund cell therapy R&Dhttps://pharmaphorum.com/news/allogene-astounds-wall-street-with-324m-ipo-to-fund-cell-therapy-rd/
Celltrion/Teva Rituxan biosimilar edges closer to US approvalIt looks increasingly likely that Roche’s cancer blockbuster Rituxan (rituximab) will face competition from a cheaper biosimilar in Share XCelltrion/Teva Rituxan biosimilar edges closer to US approvalhttps://pharmaphorum.com/news/celltrion-teva-rituxan-biosimilar-edges-closer-to-us-approval/
Pfizer’s leukaemia drug gets NHS funding in England and WalesPfizer’s Mylotarg has been approved by the English and Scottish NHS cost watchdogs as a restricted use treatment for Share XPfizer’s leukaemia drug gets NHS funding in England and Waleshttps://pharmaphorum.com/news/pfizers-leukaemia-drug-gets-nhs-funding-in-england-and-wales/
Celltrion’s Rituxan biosimilar gets glowing review ahead of key meetingReviewers from the FDA have given Celltrion’s biosimilar of Roche’s blood cancer blockbuster Rituxan a glowing report ahead Share XCelltrion’s Rituxan biosimilar gets glowing review ahead of key meetinghttps://pharmaphorum.com/news/celltrions-rituxan-biosimilar-gets-glowing-review-ahead-of-key-meeting/
NHS to reimburse Gilead’s CAR-T in adultsThe first CAR-T therapy aimed at adults with lymphoma is to be reimbursed in England after manufacturer Gilead Share XNHS to reimburse Gilead’s CAR-T in adultshttps://pharmaphorum.com/news/nhs-to-reimburse-gileads-car-t-in-adults/
Lilly’s breast cancer drug Verzenio approved in EUEli Lilly’s Verzenio breast cancer drug has been approved in Europe, as the pharma prepares to compete with Share XLilly’s breast cancer drug Verzenio approved in EUhttps://pharmaphorum.com/news/lillys-breast-cancer-drug-verzenio-approved-in-eu/
FDA says Clovis’ Rubraca could be prostate cancer breakthroughClovis Oncology’s Rubraca (rucaparib) has been designated as a Breakthrough Therapy by the FDA in prostate cancer, paving Share XFDA says Clovis’ Rubraca could be prostate cancer breakthroughhttps://pharmaphorum.com/news/fda-says-clovis-rubraca-could-be-prostate-cancer-breakthrough/
